Middle East Diagnostic Reagents For Infectious Diseases Market (2025 - 2033)

Middle East Diagnostic Reagents For Infectious Diseases Market Summary

The Middle East diagnostic reagents for infectious diseases market size was estimated at USD 77.92 million in 2024, and is projected to reach USD 158.14 million by 2033, growing at a CAGR of 7.6% from 2025 to 2033. The market is being driven by an increase in regulatory authorizations for multiplex and high-sensitivity infectious disease reagent kits, as well as the expansion of national public-health and reference laboratories throughout the Middle East.

These factors are improving regional diagnostic capacity, allowing for faster detection of new and re-emerging pathogens. In 2024, WHO EMRO designated Saudi Arabia's Public Health Laboratory as a National Influenza Centre, increasing surveillance readiness and driving demand for validated, quality-assured diagnostic reagents. These developments, taken together, support the widespread use of advanced reagent platforms, particularly molecular and immunodiagnostic assays, in public health networks and clinical laboratories.

The Middle East diagnostic reagents market is being driven by increased regulatory approvals for multiplex and high-sensitivity kits, as well as the growth of national public-health and reference laboratories. Regulatory endorsements, such as Thermo Fisher Scientific's FDA-approved respiratory pathogen panels, which was implemented in UAE laboratories in 2024, boost confidence in advanced reagent use. The expansion of national laboratories in 2023, including Egypt's Central Public Health Laboratory, which is expected to ramp up molecular testing and, improves pathogen surveillance capabilities. These developments allow for faster sample processing, broader geographic coverage, and increased procurement of validated reagents. Government-led investments in laboratory infrastructure enable smaller hospitals and clinics to perform sophisticated diagnostic testing. By combining regulatory support with expanded laboratory reach, the region ensures that multiplex, high-sensitivity reagents are available in both the public and private sectors, strengthening preparedness against endemic and emerging infectious diseases.

The market is being driven by the adoption of multiplex testing and automated platforms, which improve diagnostic throughput and shorten turnaround times. Multiplex reagents enable the simultaneous detection of multiple pathogens from a single sample, saving reagents and increasing operational efficiency. For instance, IDT's integrated PCR reagent panels, which were introduced in Bahraini laboratories in 2025, enable rapid detection of respiratory and enteric pathogens, allowing for same-day results. Automated platforms, such as SeraCare's AccuPlex systems, improve nucleic acid extraction, amplification, and reporting while reducing manual labor and human error. These technologies allow laboratories to process larger sample volumes, which is critical during sudden outbreaks or seasonal epidemics. As a result, reagent utilization rises alongside faster, more reliable diagnostics, meeting the growing clinical and public-health demand for high-throughput solutions. Automation and multiplexing are accelerating market adoption by enabling cost-effective, accurate, and rapid infectious disease testing throughout the region.

The growing need for AMR surveillance is a significant driver of reagent demand. Multiplex bacterial-resistance gene detection kits are essential for identifying pathogens with resistance genes such as NDM, KPC, and OXA variants, thereby promoting rational antibiotic use. Bio-Rad Laboratories' multiplex AMR panels were installed in Qatar's Hamad Medical Corporation in 2024, allowing hospitals to track resistance trends in real time. Regional health authorities use these reagents for population surveillance, outbreak management, and stewardship programs. Continuous monitoring informs treatment guidelines and slows the spread of resistant strains, increasing the need for high-quality reagents. As hospitals and public health labs incorporate these kits into routine workflows, their use increases steadily. AMR-focused diagnostics ensure that laboratories can efficiently provide actionable insights, while also assisting national health systems in combating the growing threat of drug-resistant infections in both clinical and community settings.

In addition, persistent infectious disease burdens and outbreak risks continue to fuel the Middle Eastern reagents market. High-sensitivity kits are critical for the rapid detection of emerging and endemic pathogens, especially in areas with frequent mass gatherings. For instance, Kuwait expanded Dengue virus testing in 2025 in response to local outbreaks, highlighting the importance of rapid, multiplex reagents in outbreak containment. Similarly, the region's vulnerability to MERS-CoV and seasonal influenza drives up demand for sensitive respiratory pathogen panels. Manufacturers are responding with specialized reagents that can detect multiple viral and bacterial agents at the same time, allowing for earlier diagnosis, more timely intervention, and better patient management. The combination of high disease prevalence, mobile populations, and public-health preparedness initiatives ensures consistent demand for validated diagnostic reagents, which fuels the market's expansion.

Market Concentration & Characteristics

The Middle East market is known for its high level of innovation, which is fueled by multiplex and high-sensitivity nucleic acid reagent kits that allow for the simultaneous detection of multiple pathogens in a single sample. Automated platforms, such as BGI Genomics' PM Easy Lab, can complete nucleic acid extraction, detection, and reporting in 90 minutes. These advancements reduce manual labor, shorten turnaround times, and improve diagnostic accuracy for both routine and outbreak tests. In Addition, the ongoing development of pathogen-specific reagents, such as CNS, respiratory, and bacterial resistance panels to meet emerging clinical needs while also strengthening regional public health preparedness.

M&A activity in the Middle East diagnostic reagents market is medium, with international and regional players generally preferring strategic collaborations and partnerships to large-scale acquisitions. These partnerships enable businesses to share expertise, expand technological capabilities, and enter local markets without taking on the full financial and regulatory risk of mergers. Smaller regional acquisitions do occur, but the overall landscape favors collaborative approaches to accelerate product availability, integrate innovative reagent technologies, and improve diagnostic services across existing laboratory networks. The moderate level of M&A activity reflects both the opportunities and challenges of operating in a region with disparate healthcare systems and infrastructure levels.

Regulatory frameworks in the Middle East have a significant impact on the diagnostic reagent market. National authorities, such as the Saudi Food and Drug Authority (SFDA), approve multiplex pathogen panels and AMR detection kits to ensure product safety, reliability, and clinical credibility. Adoption is driven by stringent regulatory compliance in hospitals, public health laboratories, and research centers. Delays or variations in approval processes can slow market entry, but positive regulatory decisions can significantly speed up procurement, expand clinical use, and boost trust in high-sensitivity reagents. As a result, regulatory guidance is a critical driver of market growth, influencing both product availability and adoption rates.

The Middle East diagnostic reagents market is experiencing medium product expansion, with pathogen-specific and multiplex reagent kits becoming more widely available. Manufacturers continuously create new reagent panels, including respiratory pathogen panels, CNS infection assays, and antimicrobial resistance gene detection kits, to meet changing clinical needs and emerging infectious threats. However, high development and validation costs, the need for regulatory clearance, and local laboratory readiness all limit the rate of expansion. The growing variety of reagents allows laboratories to screen for multiple pathogens from a single sample, improving their ability to integrate comprehensive infectious disease diagnostics into routine workflows and outbreak response protocols.

Regional growth is slow to medium, hampered by limited laboratory infrastructure and labor shortages in remote or underserved Middle Eastern regions. While Saudi Arabia, Kuwait, and the UAE are expanding public-health laboratories and testing capacity, smaller countries and rural areas face challenges in implementing high-sensitivity reagent kits. Logistics, cold chain requirements, and the availability of trained personnel continue to be significant barriers. However, gradual infrastructure development and international partnerships are allowing for selective regional expansion, particularly in urban hubs and national reference laboratories, gradually increasing the availability of advanced diagnostic reagents throughout the Middle East.

Product Insights

The molecular reagents segment led the diagnostic reagents for infectious diseases market in 2024 with a share of 21.04%, owing to the superior sensitivity and specificity of molecular assays such as PCR and NGS-based tests, which allow for early and accurate pathogen detection. Molecular reagents provide rapid turnaround, the ability to detect multiple pathogens or resistance genes in a single run, and consistent performance even in low-viral-load or asymptomatic cases, which immunoassays and antigen tests may not. This makes them particularly useful in clinical diagnostics and public-health surveillance, where early detection and precise identification of infectious agents (including emerging or drug-resistant pathogens) is crucial.

The rapid test reagent segment is projected to show the fastest growth over the forecast period in the diagnostic reagents for infectious diseases market, because of rising demand for decentralized testing, expanded public-health screening programs, and an increased need for rapid pathogen detection during outbreaks. Fast-acting immunoassay reagents used in point-of-care kits allow for quick diagnosis of tropical, respiratory, and gastrointestinal infections, making them useful in both clinical and field settings. The UAE's establishment of a domestic rapid test manufacturing facility in September 2024, which produces reagent-embedded kits for dengue NS1, HCV, malaria, strep A, RSV, chikungunya, and Zika, demonstrates how localized production improves reagent availability. This expansion ensures supply security, reduces procurement delays, and speeds up regional adoption of rapid diagnostic reagents.

Disease Area Insights

The respiratory infections segment led the market with the largest revenue share of 25.98% in 2024, owing to the high prevalence and recurring outbreaks of viral and bacterial respiratory pathogens in Middle Eastern countries. The rising prevalence of MERS-CoV, influenza, RSV, and other acute respiratory infections continues to put strain on hospital and laboratory infrastructure. The demand for rapid, high-sensitivity diagnostic reagents is increasing as regional surveillance programs are strengthened, multiplex PCR panels are widely adopted, and public health is better prepared for emerging respiratory threats. The WHO outbreak update for 2025 identified new clusters of severe respiratory infections in the region, while recent Middle Eastern clinical findings highlight the persistent circulation of influenza and RSV, emphasizing the need for scalable, accurate respiratory-testing reagents.

The vector-borne & tropical diseases segment is expected to grow at the fastest CAGR during the forecast period, due to rising cases of dengue, West Nile fever, Crimean-Congo hemorrhagic fever (CCHF), and leishmaniasis in countries such as Saudi Arabia, the UAE, Oman, and Iraq. Climate change, growing sandfly and mosquito populations, rapid urbanization, and increased cross-border population movement are all escalating transmission risks. The region's governments are strengthening surveillance networks and outbreak response systems, resulting in a greater demand for rapid, accurate, and field-ready diagnostic solutions tailored to regional vector-borne disease patterns.

Technology Insights

The molecular diagnostics segment represented the largest share of 29.41% in 2024. The high sensitivity and specificity of nucleic-acid-based assays, which allow for accurate pathogen detection even at low viral loads, as well as the growing demand for multiplex PCR panels capable of detecting multiple infections at once. Growing awareness about early detection, expanded testing capacities in public health labs, and increased adoption of PCR workflows in hospitals and private diagnostic centers all contribute to this growth. For instance, a 2025 strategic MoU by Co‑Diagnostics, Inc. to introduce its CO-Dx PCR platform to the Kingdom of Saudi Arabia demonstrates how international partnerships directly expand molecular reagent availability and accessibility in the Middle East diagnostic reagents market.

The point-of-care reagents segment is expected to show the fastest growth during the forecast period, driven by an increasing need for quick, on-site diagnostics in both hospitals and community environments. A growing awareness regarding the importance of early identification and prompt treatment of infectious diseases has led healthcare providers to embrace POC testing, which shortens turnaround times in comparison to centralized laboratory testing. The persistent outbreaks of respiratory illnesses, vector-borne diseases, and antimicrobial-resistant pathogens in the Middle East further underscore the necessity for portable, highly sensitive reagents. In addition, advancements in technology related to miniaturized immunoassays, molecular diagnostics, and automated POC platforms are facilitating the development of more precise, user-friendly, and scalable testing solutions, enhancing market adoption.

End Use Insights

The hospitals and clinics segment led the market with the largest revenue share of 24.17% in 2024, supported by their role as primary centers for infectious disease diagnosis, continuous patient inflow, and the need for rapid, high-accuracy testing during both routine care and outbreak situations. Middle Eastern hospitals are increasingly relying on molecular and rapid immunoassay reagents to treat large numbers of respiratory, vector-borne, and gastrointestinal infections. Expanding laboratory infrastructure, government-backed quality-accreditation programs, and the integration of automated analyzers all improve reagent utilization. Hospital-based stewardship initiatives and rising demand for same-day diagnostic decisions are driving increased adoption of pathogen-specific reagent panels, cementing the segment's dominant position in the regional diagnostic reagents market.

The diagnostic laboratories segment is expected to expand to a significant CAGR of 7.9% due to rising testing volumes, increased adoption of high-sensitivity molecular reagents, and rapid modernization of laboratory infrastructure in the Middle East. The growing reliance on multiplex PCR panels for respiratory, gastrointestinal, and vector-borne pathogens drives up reagent consumption, while regulatory emphasis on quality assurance reinforces the need for validated, standardized assay kits. Regional investments aimed at improving turnaround times and expanding specialized infectious disease testing capabilities drive the segment's growth. For instance, in August 2025, Wimpey Laboratories' cutting-edge molecular testing facility in Dubai, which improves regional diagnostic capacity through advanced DNA/RNA technologies, expanded pathogen detection services, and increased technical expertise. This expansion, which includes over 200 experts and cutting-edge platforms, accelerates molecular workflow adoption while also increasing demand for high-performance infectious disease reagents. Consumable reagent usage is expected to rise steadily throughout the Gulf and wider Middle East region as laboratories integrate automation, digital workflow tools, and broader pathogen-screening menus.

Country Insights

The diagnostic reagents for infectious diseases market in the Middle East and Africa is growing slowly, owing to constraints such as insufficient laboratory capacity, a lack of trained personnel, rising costs, and affordability issues that impede the adoption of advanced testing technologies. Despite these constraints, the sector is gradually progressing, because to increased awareness of early detection, increased government and donor-backed initiatives, and a significant infectious disease burden that is growing across the region. Moreover, multiple factors are accelerating the emergence and spread of infectious diseases, including population displacement, socioeconomic disparities, environmental changes, shifts in land and water use, and a high prevalence of metabolic and other comorbid conditions. Cross-border mobility in high-risk areas, large-scale gatherings, and evolving human-animal interactions drive up demand for dependable diagnostic reagents, creating new opportunities for market development and investment.

Saudi Arabia Diagnostic Reagents For Infectious Diseases Market Trends

The diagnostic reagents for infectious disease testing market in Saudi Arabia is largely propelled by the strong expansion of molecular diagnostic technologies, especially PCR-based systems, which continue to account for the majority of reagent utilization. Demand remains high due to the country’s increasing infectious disease burden, the lasting impact of the COVID-19 pandemic, and a heightened national focus on pathogen monitoring. Large-scale government efforts under Vision 2030, along with substantial investments in healthcare modernization and laboratory infrastructure upgrades, have supported consistently high reagent uptake across both public and private healthcare settings.

UAE Diagnostic Reagents For Infectious Diseases Market Trends

The diagnostic reagents for infectious diseases market in UAE is driven by the increasing use of advanced point-of-care and high-sensitivity testing technologies, rising demand for rapid diagnostics in hospitals and laboratories, and ongoing investments in improving national infectious disease detection capacity. The growing emphasis on early pathogen detection, faster clinical decision-making, and decentralized testing is driving up reagent consumption across public and private healthcare networks. This momentum is bolstered by the introduction of novel reagent platforms, which are showcased at major regional events such as Medlab Middle East.In January 2025, Anbio Biotechnology presented a full suite of next-generation POCT solutions including dry chemiluminescence immunoassay reagents, immunofluorescence-based infectious-disease panels, dry biochemistry strips, and colloidal-gold rapid tests specifically designed to enhance sensitivity, stability, and testing efficiency. These products support room-temperature transport, multi-parameter pathogen detection, and quick turnaround times, making them ideal for UAE emergency departments, pharmacies, mobile health units, and high-volume clinical labs. Their introduction improves the country's ability to conduct scalable molecular and immunoassay testing, resulting in sustained demand for innovative, high-performance diagnostic reagents.

Kuwait Diagnostic Reagents For Infectious Diseases Market Trends

The diagnostic reagents for infectious diseases market in Kuwait is experiencing growth due to increased investments in healthcare modernization, the enhancement of laboratory infrastructure, and a rising demand for quick and precise pathogen detection. The escalating incidence of respiratory, gastrointestinal, and vector-borne infections is resulting in a higher use of molecular and immunoassay-based reagent kits in hospitals, clinics, and public health laboratories. A strengthened government emphasis on epidemic preparedness, regular surveillance, and timely outbreak detection is further propelling the adoption of multiplex and high-sensitivity reagent technologies. Moreover, the trend towards decentralized testing, the integration of automated systems, and the need for quicker turnaround times are motivating laboratories to shift from traditional methods to advanced reagent-based solutions, thereby supporting ongoing market growth in Kuwait.

Oman Diagnostic Reagents For Infectious Diseases Market Trends

The diagnostic reagents for infectious diseases market in Oman is growing as the nation intensifies its development of healthcare infrastructure and bolsters its public health capabilities. The rising incidence of infectious diseases, such as respiratory infections, vector-borne diseases, and newly emerging pathogens, is increasing the need for high-sensitivity and multiplex reagent kits. Government efforts aimed at enhancing disease surveillance, outbreak readiness, and laboratory diagnostic capacity are further fueling the growth of the market. Hospitals, diagnostic facilities, and public health laboratories are increasingly utilizing automated systems and multiplex testing technologies to improve both throughput and precision. Furthermore, the emphasis on monitoring antimicrobial resistance, swiftly identifying pathogens, and incorporating diagnostic reagents into national health initiatives is driving the growth of the infectious disease reagents market throughout Oman.

Qatar Diagnostic Reagents For Infectious Diseases Market Trends

The diagnostic reagents for infectious diseases market in Qatar is driven by a mix of heightened awareness about diseases, an improvement in public health surveillance systems, and a growing need for quick and dependable diagnostic tools. The increasing cases of respiratory, gastrointestinal, and vector-borne infections heighten the demand for highly sensitive molecular and immunoassay reagents. Initiatives by the government to enhance readiness for outbreaks and incorporate comprehensive diagnostic testing into national health initiatives further catalyze the adoption of reagents. The increasing expatriate demographic and the rise in travel to and from Qatar lead to the introduction of imported infections, thereby creating a need for broad-spectrum pathogen detection kits. Moreover, the heightened emphasis on monitoring antimicrobial resistance amplifies the demand for multiplex and resistance-gene detection reagents, positioning Qatar as an important market for the growth of infectious disease diagnostics.

Key Middle East Diagnostic Reagents For Infectious Diseases Company Insights

The Middle East diagnostic reagents for infectious diseases market features several influential players that are shaping innovation, clinical adoption, and technological advancement across the region. Key companies include F. Hoffmann-La Roche Ltd, Abbott, QIAGEN, bioMérieux, Bio-Rad Laboratories, Inc., Seegene Inc., Thermo Fisher Scientific, Inc., SD Biosensor, Mindray, Astragene, and Hologic, all of which contribute significantly through high-sensitivity molecular assays, rapid antigen and antibody reagents, multiplex PCR panels, and advanced immunoassay solutions. These firms continue to expand their presence through enhanced reagent formulations, automation-ready platforms, pathogen-specific detection kits, and improved turnaround times for critical infectious disease testing.

In addition, the companies are strengthening their market position through strategic partnerships, regional collaborations, distributor expansions, and clinical validation programs with leading hospitals, reference laboratories, and public health institutions throughout the Middle East. Their ongoing investments in R&D, biosurveillance systems, laboratory infrastructure, and rapid-response diagnostic workflows all contribute to the rapid adoption and evolution of infectious disease testing in the region.

Recent Developments

• In October 2024, SFDA CEO launched an initiative to develop infectious disease diagnostic reagents and advance 3D printing in hospitals, aiming to boost innovation, reduce costs, strengthen national production, and support research.

• In February 2023, BGI Genomics strengthened its infectious disease reagent portfolio in the Middle East after its multiplex nucleic acid test kits received market authorization from the Saudi Food & Drug Authority (SFDA). The approved reagents include the multiplex bacterial resistance gene detection kit, the multiplex nucleic acid reagent for respiratory pathogens, and the CNS pathogen identification reagent panel, all of which increase the availability of high-sensitivity diagnostic solutions in local laboratories.

• In May 2022, Saudi Arabia requested MPV testing kits from BGI as part of its ongoing public health preparedness efforts. BGI quickly supplied the kits, and its technical team in Saudi Arabia assisted with validation and performance testing to ensure a smooth transition into local laboratories. In addition, in July 2022, these reagents were used to identify the Kingdom's first case of imported monkeypox. The patient was treated in Riyadh, and all identified close contacts later tested negative.

Middle East Diagnostic Reagents For Infectious Diseases Market